In 2018, around 270,000 Canadians were living with inflammatory bowel disease (IBD), which comprises Crohn’s disease and ulcerative colitis. Several drug classes, including corticosteroids, immunomodulators and anti-inflammatory biologics, can induce and maintain remission of IBD. CADTH has undertaken a series of reviews of the clinical and economic evidence surrounding drugs for IBD to clarify their relative place in therapy and inform appropriate reimbursement criteria by public drug plans.
Appropriate Pharmacotherapy for Inflammatory Bowel Disease
Last updated: June 6, 2019
Project Number: HO0003-000 - HE0018-000
Product Line: Technology Review
Result type: Report